These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 18751872)

  • 21. Thyroidal triiodothyronine and thyroxine in Graves' disease: correlation with presurgical treatment, thyroid status, and iodine content.
    Larsen PR
    J Clin Endocrinol Metab; 1975 Dec; 41(06):1098-104. PubMed ID: 54364
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Significance of thyroid blood flow as a predictor of methimazole sensitivity in untreated hyperthyroid patients with Graves' disease.
    Nagasaki T; Inaba M; Kumeda Y; Fujiwara-Ueda M; Hiura Y; Nishizawa Y
    Biomed Pharmacother; 2007 Sep; 61(8):472-6. PubMed ID: 17420111
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Soluble intercellular adhesion molecule-1 (sICAM-1) concentrations in Graves' disease patients followed up for development of ophthalmopathy.
    De Bellis A; Di Martino S; Fiordelisi F; Muccitelli VI; Sinisi AA; Abbate GF; Gargano D; Bellastella A; Bizzarro A
    J Clin Endocrinol Metab; 1998 Apr; 83(4):1222-5. PubMed ID: 9543145
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute effects of corticosteroids on thyroid activity in Graves' disease.
    Williams DE; Chopra IJ; Orgiazzi J; Solomon DH
    J Clin Endocrinol Metab; 1975 Aug; 41(2):354-61. PubMed ID: 1174132
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serum fibroblast growth factor 23 and mineral metabolism in patients with euthyroid Graves' diseases: a case-control study.
    Lin CH; Chang CK; Shih CW; Li HY; Chen KY; Yang WS; Tsai KS; Wang CY; Shih SR
    Osteoporos Int; 2019 Nov; 30(11):2289-2297. PubMed ID: 31384956
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Opposite effects of dexamethasone on serum concentrations of 3,3',5'-triiodothyronine (reverse T3) and 3,3'5-triiodothyronine (T3).
    Chopra IJ; Williams DE; Orgiazzi J; Solomon DH
    J Clin Endocrinol Metab; 1975 Nov; 41(5):911-20. PubMed ID: 1242390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Clinical studeis on the regulatory system of thyroid hormone secretion and serum triiodothyronine. Part III. Studies on thyroid hormone change and its relationship when TSH in cases with subclinical hypothyroidism (Hashimoto's thyroiditis and 131I treated Graves' disease)].
    Takeda Y
    Nihon Naibunpi Gakkai Zasshi; 1975 Feb; 51(2):85-97. PubMed ID: 808432
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Down-regulated resistin level in consequence of decreased neutrophil counts in untreated Grave's disease.
    Peng Y; Qi Y; Huang F; Chen X; Zhou Y; Ye L; Wang W; Ning G; Wang S
    Oncotarget; 2016 Nov; 7(48):78680-78687. PubMed ID: 27637079
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum ratio of triiodothyronine to thyroxine, and thyroxine-binding globulin and calcitonin concentrations in Graves' disease and destruction-induced thyrotoxicosis.
    Amino N; Yabu Y; Miki T; Morimoto S; Kumahara Y; Mori H; Iwatani Y; Nishi K; Nakatani K; Miyai K
    J Clin Endocrinol Metab; 1981 Jul; 53(1):113-6. PubMed ID: 6165731
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Behavior of soluble intercellular adhesion molecule-1 and endothelial-leukocyte adhesion molecule-1 concentrations in patients with Graves' disease with or without ophthalmopathy and in patients with toxic adenoma.
    De Bellis A; Bizzarro A; Gattoni A; Romano C; Di Martino S; Sinisi AA; Abbadessa S; Bellastella A
    J Clin Endocrinol Metab; 1995 Jul; 80(7):2118-21. PubMed ID: 7541801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Serum thyrotropin receptor antibodies concentrations in patients with Graves' disease before, at the end of methimazole treatment, and after drug withdrawal: evidence that the activity of thyrotropin receptor antibody and/or thyroid response modify during the observation period.
    Carella C; Mazziotti G; Sorvillo F; Piscopo M; Cioffi M; Pilla P; Nersita R; Iorio S; Amato G; Braverman LE; Roti E
    Thyroid; 2006 Mar; 16(3):295-302. PubMed ID: 16571093
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The iodine perchlorate discharge test before and after one year of methimazole treatment of hyperthyroid Graves' disease.
    Roti E; Minelli R; Gardini E; Bianconi L; Salvi M; Gavaruzzi G; Ugolotti G; Braverman LE
    J Clin Endocrinol Metab; 1994 Mar; 78(3):795-9. PubMed ID: 8126159
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A retrospective cohort study: do patients with graves' disease need to be euthyroid prior to surgery?
    Al Jassim A; Wallace T; Bouhabel S; Majdan A; Hier M; Forest VI; Payne R
    J Otolaryngol Head Neck Surg; 2018 May; 47(1):37. PubMed ID: 29784035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Increase of interferon-γ inducible CXCL9 and CXCL11 serum levels in patients with active Graves' disease and modulation by methimazole therapy.
    Antonelli A; Ferrari SM; Corrado A; Ferrannini E; Fallahi P
    Thyroid; 2013 Nov; 23(11):1461-9. PubMed ID: 23721189
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Concentrations of soluble vascular cell adhesion molecule-1 (sVCAM-1) in patients witt Graves' disease and thyroid associated orbitopathy].
    Kulig G; Pilarska K; Kulig J
    Przegl Lek; 2004; 61(12):1319-24. PubMed ID: 15850321
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Response to methimazole in Graves' disease. The European Multicenter Study Group.
    Benker G; Vitti P; Kahaly G; Raue F; Tegler L; Hirche H; Reinwein D
    Clin Endocrinol (Oxf); 1995 Sep; 43(3):257-63. PubMed ID: 7586593
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ratio of serum triiodothyronine to thyroxine and the prognosis of triiodothyronine-predominant Graves' disease.
    Takamatsu J; Sugawara M; Kuma K; Kobayashi A; Matsuzuka F; Mozai T; Hershman JM
    Ann Intern Med; 1984 Mar; 100(3):372-5. PubMed ID: 6546484
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decreased serum level of IL-7 in patients with active Graves' disease.
    Motylewska E; Nieć M; Siejka A; Komorowski J; Ławnicka H; Świętosławski J; Stępień H
    Cytokine; 2015 Oct; 75(2):373-9. PubMed ID: 26113403
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subclinical Graves' disease as a cause of subnormal TSH levels in euthyroid subjects.
    Kasagi K; Takeuchi R; Misaki T; Kousaka T; Miyamoto S; Iida Y; Konishi J
    J Endocrinol Invest; 1997 Apr; 20(4):183-8. PubMed ID: 9211123
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Increase of interferon-gamma-inducible CXC chemokine CXCL10 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.
    Antonelli A; Rotondi M; Fallahi P; Romagnani P; Ferrari SM; Barani L; Ferrannini E; Serio M
    Clin Endocrinol (Oxf); 2006 Feb; 64(2):189-95. PubMed ID: 16430719
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.